Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
768.520.22%
QQQ
719.470.07%
BTC/USD
78823.710.3371%
DIA
530.240.72%
GLD
403.160.89%
TLT
81.950.32%

Kailera Therapeutics Inc

KLRANASDAQ
Trade with Public
Trade with Public
$16.23
0.493.11%
At close: Sep 3, 5:00 PM EST
$16.00
0.261.65%
Pre-Market: 6:15 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Kailera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kailera Therapeutics (KLRA).

Price Target Range — 1 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$38Upside to Avg. PT+137.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 12, 2026Leerink PartnersDavid RisingerInitiateOutperform$36
May 12, 2026JefferiesRoger SongInitiateBuy$48
More with Benzinga EdgeGet Access

Analyst Ratings News

Why Is Kailera Therapeutics Stock Falling Tuesday?

Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.
Vandana Singh

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
Vandana Singh

PRO
Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36

Leerink Partners analyst David Risinger initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating and announces Price Target of $36.
Benzinga Newsdesk

PRO
Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48

Jefferies analyst Roger Song initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $48.
Benzinga Newsdesk

PRO
Evercore ISI Group Initiates Coverage On Kailera Therapeutics with Outperform Rating

Evercore ISI Group analyst Umer Raffat initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating.
Benzinga Newsdesk

This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved